1
|
Alawad MJ, Almayoof M, Al Bozom A, Alkhidir T, Emam SS, Farfar K. Post-malaria neurological syndrome (PMNS): a rare case report with brain biopsy findings. BMC Infect Dis 2023; 23:886. [PMID: 38114951 PMCID: PMC10729502 DOI: 10.1186/s12879-023-08704-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 10/12/2023] [Indexed: 12/21/2023] Open
Abstract
Post-malaria neurological syndrome (PMNS) is a rare, self-limiting condition that presents with a wide range of neurological manifestations after clearance of malarial infection, especially 𝘗𝘭𝘢𝘴𝘮𝘰𝘥𝘪𝘶𝘮 f𝘢𝘭𝘤𝘪𝘱𝘢𝘳𝘶𝘮, most patients recover without residual deficits. Here we present a case of a 29-year-old, male with a recent history of malaria treated successfully, who presented due to a generalized tonic-clonic seizure, without any other neurological symptoms, the examination and labs were unremarkable, he underwent a computer tomography (CT) scan and Magnetic resonant imaging (MRI) which both showed two areas of vasogenic edema involving the subcortical white matter of left frontal and right posterior parasagittal regions, all autoimmune screens, infection workup from blood and CSF were negative, he underwent a brain biopsy that showed intense perivascular inflammation with neuronal loss and gliosis, findings are nonspecific and can be seen in a variety of condition. The patient's condition improved, and he was discharged without any complications.
Collapse
Affiliation(s)
- Mouhammad J Alawad
- Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation, Doha, 3050, Qatar.
| | - Moustafa Almayoof
- Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation, Doha, 3050, Qatar
| | - Adel Al Bozom
- Department of Medical Education, Internal Medicine Residency Program, Hamad Medical Corporation, Doha, 3050, Qatar
| | - Taha Alkhidir
- Department of Medicine, Division of Neurology, Hamad Medical Corporation, Doha, Qatar
| | - Saeed S Emam
- Department of clinical radiology, Hamad Medical Corporation, Doha, Qatar
| | - Khalifa Farfar
- Department of Medicine, Al Wakra hospital, Hamad Medical Corporation, Doha, Qatar
| |
Collapse
|
2
|
Habas E, Al Adab A, Arryes M, Alfitori G, Farfar K, Habas AM, Akbar RA, Rayani A, Habas E, Elzouki A. Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates. Cureus 2023; 15:e46737. [PMID: 38022248 PMCID: PMC10631488 DOI: 10.7759/cureus.46737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/09/2023] [Indexed: 12/01/2023] Open
Abstract
Chronic kidney disease (CKD) is caused by hypoxia in the renal tissue, leading to inflammation and increased migration of pathogenic cells. Studies showed that leukocytes directly sense hypoxia and respond by initiating gene transcription, encoding the 2-integrin adhesion molecules. Moreover, other mechanisms participate in hypoxia, including anemia. CKD-associated anemia is common, which induces and worsens hypoxia, contributing to CKD progression. Anemia correction can slow CKD progression, but it should be cautiously approached. In this comprehensive review, the underlying pathophysiology mechanisms and the impact of renal tissue hypoxia and anemia in CKD onset and progression will be reviewed and discussed in detail. Searching for the latest updates in PubMed Central, Medline, PubMed database, Google Scholar, and Google search engines were conducted for original studies, including cross-sectional studies, cohort studies, clinical trials, and review articles using different keywords, phrases, and texts such as "CKD progression, anemia in CKD, CKD, anemia effect on CKD progression, anemia effect on CKD progression, and hypoxia and CKD progression". Kidney tissue hypoxia and anemia have an impact on CKD onset and progression. Hypoxia causes nephron cell death, enhancing fibrosis by increasing interstitium protein deposition, inflammatory cell activation, and apoptosis. Severe anemia correction improves life quality and may delay CKD progression. Detection and avoidance of the risk factors of hypoxia prevent recurrent acute kidney injury (AKI) and reduce the CKD rate. A better understanding of kidney hypoxia would prevent AKI and CKD and lead to new therapeutic strategies.
Collapse
Affiliation(s)
| | - Aisha Al Adab
- Internal Medicine, Hamad General Hospital, Doha, QAT
| | - Mehdi Arryes
- Internal Medicine, Hamad General Hospital, Doha, QAT
| | | | | | - Ala M Habas
- Internal Medicine, Tripoli University, Tripoli, LBY
| | - Raza A Akbar
- Internal Medicine, Hamad General Hospital, Doha, QAT
| | - Amnna Rayani
- Hemat-oncology Department, Pediatric Tripoli Hospital, Tripoli University, Tripoli, LBY
| | - Eshrak Habas
- Internal Medicine, Tripoli University, Tripoli, LBY
| | | |
Collapse
|
3
|
Habas E, Ali E, Farfar K, Errayes M, Alfitori J, Habas E, Ghazouani H, Akbar R, Khan F, Al Dab A, Elzouki AN. IgA nephropathy pathogenesis and therapy: Review & updates. Medicine (Baltimore) 2022; 101:e31219. [PMID: 36482575 PMCID: PMC9726424 DOI: 10.1097/md.0000000000031219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND IgA nephropathy (IgAN) is the most frequent type of primary glomerulonephritis since the first type was described more than four decades ago. It is the prevalent cause of primary glomerular disease that causes end-stage renal disease. In most patients with IgAN, hematuria is the most common reported symptom, particularly in those with a preceding upper respiratory tract infection. Although the pathogenesis of IgAN is usually multifactorial, autoimmune complex formation and inflammatory processes are the most widely recognized pathogenic mechanisms. Multiple approaches have been trialed as a therapy for IgAN, including tonsillectomy, steroids, other immune-suppressive therapy in different regimens, and kidney transplantation. AIM AND METHOD PubMed, Google, Google Scholar, Scopus, and EMBASE were searched by the authors using different texts, keywords, and phrases. A non-systemic clinical review is intended to review the available data and clinical updates about the possible mechanism(s) of IgAN pathogenesis and treatments. CONCLUSION IgAN has a heterogeneous pattern worldwide, making it difficult to understand its pathogenesis and treatment. Proteinuria is the best guide to follow up on the IgAN progression and treatment response. Steroids are the cornerstone of IgAN therapy; however, other immune-suppressive and immune-modulative agents are used with a variable response rate. Kidney transplantation is highly advisable for IgAN patients, although the recurrence rate is high. Finally, IgAN management requires collaborative work between patients and their treating physicians for safe long-term outcomes.
Collapse
Affiliation(s)
- Elmukhtar Habas
- Hamad General Medicine, Doha, Qatar
- *Correspondence: Elmukhtar Habas, Internal Medicine, Hamad Medical Corporation, AL-Rayyan Road, PO Box 3050, Doha, Qatar (e-mail: )
| | - Elrazi Ali
- Hamad General Hospital, Medicine Department, Doha, Qatar
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
A novel rapid spreading and changing virus called SARS-CoV-2 appeared in Wuhan city in December 2019. It was announced by the World Health Organization (WHO) as a pandemic disease in March 2020. It commonly presents with respiratory symptoms; however, it may be asymptomatic. Electrolyte abnormalities are not uncommon features of SARS-CoV-2 infection. Hyponatremia is one of these electrolyte disturbances among SARS-CoV-2 patients, and it may produce symptoms such as weakness and seizure as the initial presenting symptoms. The underlying mechanism(s) of hyponatremia due to SARS-CoV-2 infection is (are) not established. The aim of this review is to evaluate the possible mechanism of hyponatremia in patients with COVID-19. Understanding and categorizing the hyponatremia in these patients will lead to better treatment and correction of the hyponatremia. A review of the literature between December 2019 and March 2022 was conducted searching for the possible reported mechanism(s) of hyponatremia in SARS-CoV-2. Although SIADH is the commonly reported cause of hyponatremia in SARS-CoV-2 infection, other causes such as diarrhea, vomiting, and kidney salt loss must be considered before SIADH.
Collapse
Affiliation(s)
| | - Elrazi Ali
- Internal Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Aml Habas
- Tripoli Children Hospital, Tripoli, Libya
| | | | | | - Fahmi Khan
- Internal Medicine, Hamad Medical Corporation, Doha, Qatar
| | | | | |
Collapse
|
5
|
Al Hamoud E, Hayder Ahmed S, Alkhiyami D, Barazi R, Alrawi S, Zahrah F, Saad M, Mitwally H, Farfar K, Al Anany R. Post-discharge phone follow-up: a collaboration for optimizing medications management upon transition of care. Journal of Emergency Medicine, Trauma and Acute Care 2022. [DOI: 10.5339/jemtac.2022.qhc.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Eman Al Hamoud
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Sara Hayder Ahmed
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Dania Alkhiyami
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Raja Barazi
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Safa Alrawi
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Farah Zahrah
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Mohamed Saad
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Hassan Mitwally
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| | - Khalifa Farfar
- Internal Medicine Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar
| | - Rasha Al Anany
- Clinical Pharmacy Section, Pharmacy Department. Al-Wakra Hospital, Hamad Medical Corporation. Doha Qatar E-mail:
| |
Collapse
|